Recent News

Researchers at Vanderbilt University, the University of Texas Medical Branch at Galveston and The Scripps Research Institute for the first time have shown how human antibodies can neutralize the Marburg virus, a close cousin to Ebola. Their findings, published this week in two papers in the journal Cell, should speed development of the first effective treatment and vaccine against these often lethal viruses, said James Crowe Jr., M.D., whose team at Vanderbilt isolated and characterized the antibodies.

James Crowe Jr., M.D., left, briefs U.S. Sen. Lamar Alexander, R-Tenn., last fall on his lab’s effort to develop a potential treatment for Ebola. Vanderbilt’s cores help make such research possible, Crowe says. (photo by Anne Rayner)

October 23, 2014  -  This week, the National Academies announced the election of the Vanderbilt Vaccine Center's own Doctor Crowe to the Institute of Medicine (IOM). The now over 1900 members of the IOM serve as an advising council to the United States on health policy, practice, and research. Dr.

September 24th, 2014  -  On Wednesday, Senator Lamar Alexander visited Vanderbilt University Medical Center to meet with Dr. Crowe and his team in order to learn about the existing defenses against Ebola. Dr. Crowe and his lab conduct research which aims to develop a drug to protect individuals against the Ebola virus that has recently spread through West Africa.

Dr. Crowe will present his lecture, "Next Generation Vaccines" on Thursday, May 22, at 4 pm in 208 Light Hall as a part of Vanderbilt's Discovery Lecture series. This series seeks to respond to the requests of the Biomedical Advisory Board in presenting discussion-stimulating topics in research. Dr. Borden Lacy and Dr. Simon Mallal will also present findings that showcase Vanderbilt University's position on the cutting-edge of medical research; their lectures are respectively entitled "Structure and Function of Clostridium difficile Toxins A and B" and "Personalized Immunology."